BACKGROUND Combined oral contraceptives (COCs) reduce levels of androgen,
especially testosterone (T), by inhibiting ovarian and adrenal androgen synthesis and by …

Abstract In the United States, ovarian cancer is the fourth most frequent cause of cancer
death among women, following lung, breast, and colorectal cancers. Each year …

OBJECTIVE: To investigate how adipose tissue alters endogenous hormone levels and may
affect events at the ovarian tissue level. METHODS: We assessed current weight, weight at …

This ninety-first volume of IARC Monographscontains evaluations of the carcinogenic
hazard to humans of combined estrogen-progestogen contraceptives and combined …

Previous studies with postmenopausal women receiving oral doses of norethisterone-
containing preparations have shown that a small fraction of the dose is converted …

Abstract Selenium binding protein 1 (SELENBP1) was identified to be the most significantly
down‐regulated protein in ovarian cancer cells by a membrane proteome profiling analysis …

Ovarian cancer is the second most common gynecologic cancer among women and the
second leading cause of death from gynecologic malignancy worldwide. Androgens, acting …

The major developments in combined oral contraceptives (COCs) have been a reduction in
the total dose of both the oestrogen and progestogen administered per cycle and the …

Chronic inflammation has been implicated in a variety of cancers. In this review, we consider
associations between endometriosis and cancers both local (ovarian) and distant (breast) …

OBJECTIVES: The aim of this study was to understand the strengths and limitations of
current prevention, detection, and screening methods for ovarian cancer and to identify …